Preethi Sridhar, MD
Endocrinology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 2 carriers
- Office
- 1
Offices
1 location · Bass Medical Group · 292 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
7 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sridhar’s office at (650) 967-8841 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A119737 · Current
Licensed to practise in California · since 2012 · expires 2027-10-31 · Rajiv Gandhi University of Health Sciences, Bangalore Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$129,412
Medicare paid this office $129,412 for 189 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 31 | $63,368 | None |
| Return visit (30+ min) | 119 | $23,900 | $111 |
| Long return visit (40+ min) | 71 | $16,971 | $153 |
| Short return visit (20+ min) | 81 | $10,205 | $76 |
| Ultrasound scan of head and neck soft tissue | 39 | $4,600 | $112 |
See all 9 services
| Injection, denosumab, 1 mg | 31 | $63,368 | None |
| Return visit (30+ min) | 119 | $23,900 | $111 |
| Long return visit (40+ min) | 71 | $16,971 | $153 |
| Short return visit (20+ min) | 81 | $10,205 | $76 |
| Ultrasound scan of head and neck soft tissue | 39 | $4,600 | $112 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 120 | $3,284 | $15 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 28 | $2,156 | $29 |
| New patient visit (45+ min) | 12 | $1,803 | $150 |
| Injection of drug or substance under skin or into muscle | 32 | $769 | $14 |
Who their Medicare patients are
189 Original Medicare patients in 2024. Average age 75 · Women 63% · Also on Medicaid 0% · Health risk score 1.05. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 70% · Diabetes 43% · Coronary heart disease 27% · Chronic kidney disease 21% · Atrial fibrillation 18% · Cancer 17% · Heart failure 15% · Depression 10% · COPD 8% · Stroke 7%.
The office billed $424,431, Medicare allowed $171,636 and paid $129,412; for 4,006 services of 14 kinds; $63,368 of it was for drugs given in the office and $66,044 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 189 | 4,006 | 75 | 1.05 | $424,431 | $129,412 |
| 2023 | 182 | 3,595 | 75 | 1.00 | $345,913 | $102,380 |
| 2022 | 190 | 3,403 | 75 | 1.07 | $326,283 | $98,027 |
| 2021 | 80 | 1,645 | 76 | 1.22 | $144,544 | $43,848 |
| 2020 | 29 | 536 | 78 | 1.51 | $46,962 | $16,738 |
| 2019 | 22 | 422 | 76 | 1.37 | $14,943 | $10,100 |
| 2017 | 22 | 97 | 78 | 1.14 | $5,893 | $3,767 |
| 2016 | 15 | 146 | 75 | 1.01 | $5,341 | $3,664 |
| 2015 | 24 | 183 | 75 | 1.04 | $11,369 | $8,494 |
| 2014 | 37 | 524 | 75 | 1.48 | $20,556 | $16,063 |
| 2013 | 21 | 54 | 69 | 1.06 | $9,586 | $7,473 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Injection, denosumab, 1 mg | 33 | $55,130 | None |
| Return visit (30+ min) | 91 | $12,628 | $104 |
| Long return visit (40+ min) | 58 | $12,197 | $145 |
| Short return visit (20+ min) | 88 | $10,552 | $81 |
| Ultrasound scan of head and neck soft tissue | 34 | $4,164 | $113 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,867 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,279 | $91 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 19 | $1,215 | $29 |
| Injection of drug or substance under skin or into muscle | 34 | $721 | $14 |
2022: 10 services
| Injection, denosumab, 1 mg | 33 | $47,900 | None |
| Return visit (30+ min) | 90 | $12,822 | $114 |
| Long return visit (40+ min) | 60 | $11,979 | $156 |
| Short return visit (20+ min) | 72 | $7,275 | $79 |
| Ultrasound scan of head and neck soft tissue | 35 | $4,386 | $115 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $3,390 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $3,201 | $123 |
| New patient visit (60+ min) | 13 | $2,314 | $178 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 18 | $955 | $32 |
| Injection of drug or substance under skin or into muscle | 34 | $746 | $14 |
2021: 7 services
| Injection, denosumab, 1 mg | 15 | $23,184 | None |
| Return visit (30+ min) | 33 | $5,216 | $111 |
| New patient visit (60+ min) | 20 | $3,547 | $177 |
| Long return visit (40+ min) | 18 | $3,450 | $173 |
| Short return visit (20+ min) | 30 | $2,913 | $81 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,072 | $77 |
| Injection of drug or substance under skin or into muscle | 16 | $345 | $14 |
2020: 2 services
| Return visit (30+ min) | 14 | $3,432 | $101 |
| Short return visit (20+ min) | 14 | $1,280 | $67 |
2019: 1 service
| Return visit (30+ min) | 14 | $2,247 | $86 |
2017: 1 service
| Return visit (30+ min) | 14 | $1,435 | $90 |
2015: 1 service
| Return visit (30+ min) | 12 | $1,330 | $89 |
2014: 1 service
| Return visit (30+ min) | 12 | $1,701 | $100 |
Drugs they prescribed that Part D paid
$479,834
Pharmacies billed $479,834 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,232) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
718 generic and 398 brand-name prescriptions · $479,834 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humatrope | 15 | $109,396 | $7,293 |
| Ozempic | 36 | $65,397 | $1,817 |
| Jardiance | 34 | $52,841 | $1,554 |
| Tymlos | 12 | $46,610 | $3,884 |
| Tresiba Flextouch U-100 | 25 | $16,188 | $648 |
See all 30 drugs
| Humatrope | 15 | $109,396 | $7,293 |
| Ozempic | 36 | $65,397 | $1,817 |
| Jardiance | 34 | $52,841 | $1,554 |
| Tymlos | 12 | $46,610 | $3,884 |
| Tresiba Flextouch U-100 | 25 | $16,188 | $648 |
| Mounjaro | 17 | $15,965 | $939 |
| Lyumjev Kwikpen U-100 | 12 | $9,328 | $777 |
| Humalog Kwikpen U-100 | 16 | $8,772 | $548 |
| Nano 2nd Gen Pen Needle | 57 | $6,475 | $114 |
| Synthroid | 57 | $4,719 | $83 |
| Armour Thyroid | 20 | $2,230 | $111 |
| Levothyroxine | 130 | $1,930 | $15 |
| Liothyronine | 11 | $1,164 | $106 |
| NP Thyroid | 17 | $1,071 | $63 |
| Metformin | 73 | $942 | $13 |
| Rosuvastatin | 41 | $940 | $23 |
| Metformin Hcl Er | 60 | $749 | $12 |
| Ibandronate | 15 | $707 | $47 |
| Ramipril | 38 | $434 | $11 |
| Amlodipine Besylate | 48 | $333 | $7 |
| Losartan | 44 | $298 | $7 |
| Atorvastatin | 26 | $293 | $11 |
| Allopurinol | 14 | $254 | $18 |
| Pravastatin | 27 | $242 | $9 |
| Simvastatin | 23 | $221 | $10 |
| Acarbose | 11 | $159 | $14 |
| Hydrochlorothiazide | 23 | $148 | $6 |
| Alendronate | 19 | $145 | $8 |
| Pioglitazone | 13 | $133 | $10 |
| Glipizide Er | 11 | $125 | $11 |
Year by year
| 2024 | 1,232 | 151 | 0% (0) | 32% | $479,834 |
| 2023 | 1,209 | 173 | 0% (0) | 29% | $401,955 |
| 2022 | 845 | 169 | 0% (0) | 33% | $337,138 |
| 2021 | 296 | 70 | 0% (0) | 36% | $99,026 |
| 2020 | 141 | 18 | 0% (0) | 44% | $33,036 |
| 2019 | 77 | 19 | 0% (0) | None | $12,634 |
| 2018 | 73 | 19 | 0% (0) | 23% | $20,126 |
| 2017 | 68 | 22 | 0% (0) | None | $17,567 |
| 2016 | 38 | 11 | 0% (0) | 66% | $8,840 |
| 2015 | 40 | 15 | None | None | $9,054 |
| 2014 | 19 | None | 0% (0) | None | $10,542 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Trulicity | 21 | $57,947 | $2,759 |
| Humalog Kwikpen U-100 | 27 | $50,063 | $1,854 |
| Tymlos | 12 | $33,144 | $2,762 |
| Ozempic | 21 | $29,961 | $1,427 |
| Jardiance | 15 | $28,941 | $1,929 |
| Tresiba Flextouch U-100 | 32 | $23,241 | $726 |
| Toujeo Solostar | 14 | $9,532 | $681 |
| Nano 2nd Gen Pen Needle | 38 | $5,508 | $145 |
| Synthroid | 36 | $3,454 | $96 |
| Levothyroxine | 159 | $2,785 | $18 |
| Rosuvastatin | 54 | $2,049 | $38 |
| Metformin | 108 | $1,385 | $13 |
| NP Thyroid | 15 | $977 | $65 |
| Metformin Hcl Er | 44 | $908 | $21 |
| Ramipril | 45 | $889 | $20 |
| Methimazole | 15 | $531 | $35 |
| Losartan | 33 | $480 | $15 |
| Ezetimibe | 11 | $477 | $43 |
| Atorvastatin | 24 | $386 | $16 |
| Pioglitazone | 12 | $365 | $30 |
| Amlodipine Besylate | 53 | $341 | $6 |
| Pravastatin | 23 | $302 | $13 |
| Allopurinol | 19 | $300 | $16 |
| Alendronate | 27 | $284 | $11 |
| Glipizide Er | 19 | $256 | $13 |
| Simvastatin | 26 | $246 | $9 |
| Carvedilol | 17 | $200 | $12 |
| Lisinopril | 13 | $137 | $11 |
| Hydrochlorothiazide | 17 | $73 | $4 |
2022: 21 drugs
| Trulicity | 31 | $73,262 | $2,363 |
| Tymlos | 15 | $37,230 | $2,482 |
| Humalog Kwikpen U-100 | 12 | $21,414 | $1,784 |
| Januvia | 12 | $18,889 | $1,574 |
| Ozempic | 11 | $10,472 | $952 |
| Levothyroxine | 137 | $2,901 | $21 |
| Synthroid | 26 | $2,661 | $102 |
| Nano 2nd Gen Pen Needle | 14 | $2,248 | $161 |
| Rosuvastatin | 26 | $1,241 | $48 |
| Metformin Hcl Er | 40 | $745 | $19 |
| NP Thyroid | 11 | $655 | $60 |
| Metformin | 54 | $640 | $12 |
| Ramipril | 28 | $448 | $16 |
| Methimazole | 15 | $336 | $22 |
| Alendronate | 24 | $308 | $13 |
| Simvastatin | 23 | $228 | $10 |
| Amlodipine Besylate | 21 | $209 | $10 |
| Lisinopril | 20 | $193 | $10 |
| Losartan | 13 | $146 | $11 |
| Atorvastatin | 14 | $111 | $8 |
| Hydrochlorothiazide | 18 | $105 | $6 |
2021: 6 drugs
| Levothyroxine | 56 | $1,434 | $26 |
| NP Thyroid | 12 | $501 | $42 |
| Metformin Hcl Er | 14 | $307 | $22 |
| Lisinopril | 16 | $105 | $7 |
| Metformin | 11 | $94 | $9 |
| Amlodipine Besylate | 12 | $55 | $5 |
2020: 3 drugs
| Tirosint | 14 | $1,872 | $134 |
| Levothyroxine | 22 | $525 | $24 |
| Amlodipine Besylate | 13 | $50 | $4 |
2019: 1 drug
| Levothyroxine | 16 | $592 | $37 |
2018: 1 drug
| Levothyroxine | 16 | $643 | $40 |
2017: 2 drugs
| Levothyroxine | 14 | $475 | $34 |
| Metformin | 12 | $95 | $8 |
2016: 1 drug
| Levothyroxine | 16 | $167 | $10 |
2015: 1 drug
| Levothyroxine | 18 | $329 | $18 |
Money from drug and device companies
$1,729 in 2025
| 2025 | 19 | 71 | None | $1,729 |
| 2024 | 20 | 79 | None | $2,039 |
| 2023 | 18 | 49 | None | $1,204 |
| 2022 | 20 | 60 | None | $1,367 |
| 2021 | 5 | 7 | None | $137 |
| 2020 | 4 | 5 | None | $102 |
| 2019 | 14 | 41 | None | $761 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Evenity | $268 | 9 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $255 | 10 payments
|
| Novo Nordisk | Wegovy | $229 | 12 payments
|
| Radius Health | Tymlos | $167 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $152 | 7 payments
|
| Sanofi-Aventis U.S. | Tzield | $96 | 4 payments
|
See all 71 published payments
| Madrigal Pharmaceuticals | Meals · 2025-12-16 | Rezdiffra | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-12-16 | Rezdiffra | $6 |
| Radius Health | Meals · 2025-12-12 | Tymlos | $31 |
| Madrigal Pharmaceuticals | Meals · 2025-12-10 | Rezdiffra | $29 |
| Novo Nordisk | Meals · 2025-12-09 | Wegovy | $27 |
| Novo Nordisk | Meals · 2025-12-08 | Wegovy | $2 |
| Amgen | Meals · 2025-12-04 | Evenity | $34 |
| Amgen | Meals · 2025-12-01 | Tepezza | $33 |
| Madrigal Pharmaceuticals | Meals · 2025-11-18 | Rezdiffra | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-11-13 | Rezdiffra | $31 |
| Kyowa Kirin | Meals · 2025-11-06 | Crysvita | $29 |
| Amgen | Meals · 2025-11-03 | Repatha | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-30 | Jardiance | $24 |
| Abbvie | Meals · 2025-10-27 | Synthroid | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-10-21 | Rezdiffra | $23 |
| Amgen | Meals · 2025-10-09 | Evenity | $32 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-03 | Kerendia | $27 |
| Soleno Therapeutics | Meals · 2025-09-29 | Vykat Xr | $28 |
| Radius Health | Meals · 2025-09-25 | Tymlos | $34 |
| Madrigal Pharmaceuticals | Meals · 2025-09-22 | Rezdiffra | $40 |
| Exact Sciences | Meals · 2025-09-15 | The Cologuard Plus Collection Kit | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-11 | Jardiance | $18 |
| Xeris Pharmaceuticals | Meals · 2025-09-08 | Gvoke Hypopen | $21 |
| Sanofi-Aventis U.S. | Meals · 2025-08-28 | Tzield | $26 |
| Madrigal Pharmaceuticals | Meals · 2025-08-26 | Rezdiffra | $38 |
| Ascendis Pharma Endocrinology | Meals · 2025-08-22 | Yorvipath | $28 |
| Amgen | Meals · 2025-08-18 | Evenity | $27 |
| Sequel Med Tech | Meals · 2025-08-12 | Twiist | $33 |
| Dexcom | Meals · 2025-08-12 | Dexcom G6 Transmitter | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-04 | Jardiance | $4 |
| Madrigal Pharmaceuticals | Meals · 2025-08-04 | Rezdiffra | $24 |
| Madrigal Pharmaceuticals | Meals · 2025-08-04 | Rezdiffra | $6 |
| Sanofi-Aventis U.S. | Meals · 2025-07-31 | Tzield | $24 |
| Radius Health | Meals · 2025-07-28 | Tymlos | $21 |
| Novo Nordisk | Meals · 2025-07-22 | Rybelsus | $28 |
| Novo Nordisk | Meals · 2025-07-17 | Wegovy | $34 |
| Amgen | Meals · 2025-07-17 | Evenity | $34 |
| Ascendis Pharma Endocrinology | Meals · 2025-06-24 | Yorvipath | $30 |
| Novo Nordisk | Meals · 2025-06-23 | Wegovy | $7 |
| Lilly USA | Meals · 2025-06-04 | Mounjaro | $17 |
| Novo Nordisk | Meals · 2025-06-02 | Ozempic | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-29 | Jardiance | $26 |
| Novo Nordisk | Meals · 2025-05-24 | Wegovy | $5 |
| Novo Nordisk | Meals · 2025-05-23 | Wegovy | $7 |
| Novo Nordisk | Meals · 2025-05-23 | Rybelsus | $25 |
| Soleno Therapeutics | Meals · 2025-05-19 | Vykat Xr | $18 |
| Radius Health | Meals · 2025-05-16 | Tymlos | $33 |
| Dexcom | Meals · 2025-05-13 | Dexcom G6 Transmitter | $23 |
| Sanofi-Aventis U.S. | Meals · 2025-05-08 | Tzield | $25 |
| Lilly USA | Meals · 2025-05-07 | Mounjaro | $20 |
| Amgen | Meals · 2025-05-01 | Evenity | $22 |
| Novo Nordisk | Meals · 2025-04-24 | Wegovy | $26 |
| Radius Health | Meals · 2025-04-22 | Tymlos | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-10 | Jardiance | $28 |
| Novo Nordisk | Meals · 2025-03-28 | Ozempic | $27 |
| Xeris Pharmaceuticals | Meals · 2025-03-24 | Gvoke Hypopen | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-20 | Jardiance | $29 |
| Sanofi-Aventis U.S. | Meals · 2025-03-17 | Tzield | $20 |
| Amgen | Meals · 2025-03-13 | Evenity | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-06 | Kerendia | $29 |
| Mannkind | Meals · 2025-03-03 | Afrezza | $19 |
| Lilly USA | Meals · 2025-02-28 | Jardiance | $25 |
| Amgen | Meals · 2025-02-24 | Repatha | $23 |
| Novo Nordisk | Meals · 2025-02-22 | Ozempic | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-07 | Kerendia | $28 |
| Abbott Laboratories | Meals · 2025-02-07 | Freestyle Libre 3 | $21 |
| Medtronic | Meals · 2025-01-27 | Minimed 780g | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-23 | Jardiance | $23 |
| Radius Health | Meals · 2025-01-22 | Tymlos | $28 |
| Dexcom | Meals · 2025-01-14 | Dexcom G6 Transmitter | $23 |
| Kyowa Kirin | Meals · 2025-01-09 | Crysvita | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,039
| Lilly USA | Mounjaro | $406 | 15 payments
|
| Amgen | Evenity | $307 | 13 payments
|
| Beta Bionics | Ilet Bionic Pancreas | $254 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $215 | 9 payments
|
| Novo Nordisk | Wegovy | $175 | 8 payments
|
| Radius Health | Tymlos | $112 | 5 payments
|
| Dexcom | Dexcom G6 Transmitter | $109 | 4 payments
|
| Mannkind | Afrezza | $72 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $57 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $56 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $51 | 2 payments
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $40 | 2 payments
|
| Neurocrine Biosciences | None | $30 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $29 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $24 | 1 payment
|
| Kyowa Kirin | Crysvita | $23 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $20 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $20 | 1 payment
|
| Acella Pharmaceuticals | NP Thyroid 60 | $20 | 1 payment
|
| Vivus | Qsymia | $19 | 1 payment
|
2023: $1,204
| Lilly USA | Mounjaro | $249 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $176 | 7 payments
|
| Novo Nordisk | Rybelsus | $149 | 7 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $94 | 4 payments
|
| Radius Health | Tymlos | $91 | 3 payments
|
| Embecta | Bd Nano 2nd Gen Pen Needle | $71 | 3 payments
|
| AbbVie | Synthroid | $53 | 2 payments
|
| MannKind | Afrezza | $49 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $47 | 2 payments
|
| CeQur | Cequr Simplicity | $35 | 1 payment
|
| Amgen | Evenity | $33 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $31 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $27 | 1 payment
|
| Medtronic | Minimed 780g | $27 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $20 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $19 | 1 payment
|
| Ascensia Diabetes Care Us | None | $18 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $17 | 1 payment
|
2022: $1,367
| Lilly USA | Mounjaro | $233 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $186 | 8 payments
|
| Abbott Laboratories | Freestyle Libre 2 | $182 | 8 payments
|
| Novo Nordisk | Rybelsus | $166 | 8 payments
|
| Abbvie | Synthroid | $74 | 4 payments
|
| Alexion Pharmaceuticals | Strensiq | $64 | 3 payments
|
| Sanofi-Aventis U.S. | Toujeo | $63 | 3 payments
|
| Mannkind | Afrezza | $55 | 2 payments
|
| Medtronic | Minimed 770g | $53 | 2 payments
|
| Radius Health | Tymlos | $51 | 2 payments
|
| Becton Dickinson and | Bd Nano 2nd Gen Pen Needle | $37 | 1 payment
|
| Amgen | Prolia | $34 | 2 payments
|
| Amryt Pharma Holdings | Mycapssa | $27 | 1 payment
|
| Alfasigma USA | None | $27 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $21 | 1 payment
|
| Pfizer | Somavert | $21 | 1 payment
|
| IBSA Pharma | Tirosint | $20 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $19 | 1 payment
|
| Bigfoot Biomedical | Unity Diabetes Management System | $19 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $17 | 1 payment
|
2021: $137
| Lilly USA | Trulicity | $56 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $28 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $24 | 1 payment
|
| Novo Nordisk | Ozempic | $15 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 2 | $14 | 1 payment
|
2020: $102
| Lilly USA | Trulicity | $42 | 2 payments
|
| AbbVie | Synthroid | $26 | 1 payment
|
| Mannkind | Afrezza | $21 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $13 | 1 payment
|
2019: $761
| Lilly USA | Trulicity | $151 | 7 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $90 | 4 payments
|
| Novo Nordisk | Ozempic | $78 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $68 | 4 payments
|
| AbbVie | Synthroid | $67 | 4 payments
|
| Shire North American Group | Natpara (Parathyroid Hormone) | $66 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $64 | 4 payments
|
| Radius Health | Tymlos | $52 | 3 payments
|
| Insulet | Omnipod | $40 | 2 payments
|
| Mannkind | Afrezza | $20 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $20 | 1 payment
|
| Amgen | Prolia | $16 | 1 payment
|
| Horizon Therapeutics plc | None | $15 | 1 payment
|
| Medtronic MiniMed | Minimed 670g System | $14 | 1 payment
|
Professional record
- NPI
- 1033362041
- Licence
- CA A119737California A119737: Current · expires 2027-10-31
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 2204 Grant Rd, Suite 103, Mountain View, CA, 94040
- NPI first listed
- 2008-11-04
- NPI last updated
- 2025-02-27
- NPI record certified
- 2025-02-27
This is when the NPI record was last certified, not a medical board exam.